| Overview |
| bsm-62012r-pe-cy5-100ul |
| IRF9/ISGF3 Recombinant Monoclonal Antibody, PE-Cy5 Conjugated |
| WB, FCM |
| Human |
| Specifications |
| PE-Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Interferon regulatory factor 9 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 10379 |
| Q00978 |
| Cytoplasm, Nucleus |
| Irf9; ISGF3; ISGF3G; p48. |
| Transcription regulatory factor that mediates signaling by type I IFNs (IFN-alpha and IFN-beta). Following type I IFN binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz